B-raf Kinase Inhibitor GSK2118436 as Therapy for Patients with Metastatic Melanoma and Other Solid Tumors
CME test | Downloadable PDF | PowerPoint slides | CME Information and Faculty Disclosures |
Read Dr Love's original email (from July 6, 2010) | Subscribe to Dr Love's email alerts |
Kefford R et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Proc ASCO 2010;Abstract 8503.